Stanford medical professor Bryant Lin founded the school's Center for Asian Health Research and Education, advocating for better lung cancer screening in particular.
asserted
professor → found → screening
Then two years ago Lin became a Stage IV patient of the very disease he long crusaded against.
asserted
he → become → disease
"Super ironic that I would be co-leading the center that supports research and education in this disease, and I get diagnosed myself," he says.
asserted
he → - → disease
Lin, who is a non-smoker, tells students he considers himself lucky — even hopeful: "I think the future is really bright, because we're creating all of these personalized, specialized precision therapeutics for lung cancer," he says.
asserted
he → tell → cancer
"My hope is if we're not able to cure lung cancer, we can at least turn it into a chronic disease."
Notable improvements are shifting the prognosis for a disease once considered a death sentence.
asserted
improvements → cure → disease
Much of the recent progress is so new, it is only starting to shift the statistics on survival.
asserted
it → start → survival
While the five-year survival rate across all stages of lung cancer has doubled in three decades, it still remains at a low 30%.
asserted
it → double → %
(Stage of disease makes a huge difference; early, localized cancer survival rates over 5 years was 67% between 2015 and 2021.)
asserted
rates → make → 2015
The genetics of lung cancers are very diverse and complex relative to other cancers, making it historically tricky to treat.
asserted
it → make → cancers
One key technological development underlying many new treatments is the ability to identify, through genetic testing, the specific mutation driving a person's abnormal cell growth, according to UCLA oncologist and researcher Jonathan Goldman.
uncertain
development → underlie → Goldman
"We can pick a drug that's really been developed for that type of cancer," he says.
asserted
he → pick → cancer
Not only can that manage or even shrink tumors, because the drugs are better targeted, they also cause less collateral damage, making side effects typically more tolerable for patients.
"Survival used to be under a year, and now it's often several years and sometimes many years," Goldman says.
asserted
Goldman → manage → patients
Whether it's breast, liver or lung cancer, targeting treatments by genetic subtype is far more effective than generalized treatments of the past, Goldman says, because the medicines are designed to focus their attack on specific mutated cells driving the abnormal growth.
asserted
medicines → target → growth
Since the medicines are targeted, they also tend to have fewer harsh side effects compared to chemotherapy.
asserted
they → target → chemotherapy
Tests to identify a patient's specific cancer subtype – a procedure called comprehensive genomic testing – are already available, and Goldman served as principal investigator on a recent study published in the New England Journal of Medicine, showing dramatic reductions in recurrence, when patients with rare subtypes receive targeted medicines as their first treatment.
asserted
patients → identify → treatment
Goldman says fewer than half of lung-cancer patients in the U.S. get their cancer genetically tested prior to treatment because that evaluation is not yet considered "standard of care."
asserted
evaluation → say → care
Plus, doctors themselves may not be aware it exists; Goldman says treatment technology is changing so rapidly, general oncologists may not be up-to-date on some of the most recent developments specific to lung cancer.
uncertain
oncologists → exist → cancer
"The next step is not just these scientific discoveries, but learning how to implement these findings," he says.
asserted
he → learn → findings
"We've proven time and time again how important and effective it is to get this testing done early so you can pick your best treatment first."
asserted
you → prove → treatment
It was one of those relatively new targeted drugs, a daily pill called Tagrisso (or osimertinib), that professor-patient Bryant Lin initially began taking when he was first diagnosed in May 2024.
uncertain
he → target → May
Just three months prior to that, the Food and Drug Administration approved its use in combination with chemotherapy, based on data showing it lengthened survival.
asserted
it → approve → survival
"I am a beneficiary of years – of decades – of research," Lin says, noting how his treatment regimen has closely mapped with some of the most recent drug developments.
asserted
regimen → say → developments
"Since I've been diagnosed.
asserted
I → diagnose → ?
It's quite amazing how quick – how rapid – our advances have been occurring."
asserted
advances → occur → ?
Affordability
Treatment is one thing; affording them is another.
asserted
affording → afford → them
Even Lin, a patient with the unusual privilege of being a nationally known expert at an elite medical center, faces battles with insurance to get some of these new, expensive treatments covered.
asserted
some → know → treatments
Insurers almost always require prior authorization for the treatments, or deny coverage for new drugs that haven't yet received expert endorsement as standard protocol.
asserted
that → require → protocol
Lin says this happened for one of his $16,000 drugs, delaying his treatment at a critical time.
asserted
this → say → time
He watches patients, too, fight similar battles over coverage.
asserted
patients → watch → coverage
"Oral drugs and the IV drugs — they're hundreds of thousands of dollars," he says.
asserted
he → say → dollars
"I don't know too many people who could afford to pay out of pocket."
uncertain
who → know → pocket
A year into his treatment, the initial targeted therapy Lin was taking stopped working.
asserted
Lin → target → treatment
By then, regulators approved another drug combination – amivantamab and lazertinib – an antibody to activate the immune system, and a different pill targeting his specific mutation type, known as EGFR.
asserted
regulators → approve → EGFR
Lin, who still teaches, travels, and advises the Susan Wojcicki Foundation for lung cancer, says these new therapies have given him both more life, and one of better quality.
asserted
therapies → teach → quality
"My symptoms are really well controlled.
asserted
symptoms → control → ?
I can live my life.
asserted
I → live → life
I can speak.
asserted
I → speak → ?
I don't think I've coughed once in our conversation.
asserted
I → think → conversation
"
What's more, there's a compounding effect with this kind of scientific progress, where recent breakthroughs with other genetically similar cancers may soon apply to lung cancer.
uncertain
breakthroughs → be → cancer
One promising area of potential crossover is with pancreatic cancer, which is driven by a gene in the same KRAS family that causes a sizable minority of lung cancers.
asserted
that → drive → cancers
…and 17 more, not listed.
The Aporia
